Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 0 study of oral radiolabeled PL8177 release and absorption in the distal gastrointestinal tract
NL-OMON46068Phase 0Active, not recruiting
- Sponsor
- Palatin Technologies, Inc.
- Start
- Sep 2018
- Modality
- Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 0, open-label trial of PL8177 in autoimmune colitis (6 arms), sponsored by Palatin Technologies, Inc. Primary endpoints: Release of [14C]-PL8177 in the colon, Systemic exposure to [14C]-PL8177 and [14C]-PL8435 and 1 more. Started Sep 2018; status: active, not recruiting.
02
Drugs
PL8177
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON46068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46068.